Drug Trial Radar · NCT05630846
A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age
Last checked: Nov 20, 2026Latest source record: Jun 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
801
Actual
Start
Dec 14, 2022
Primary completion
Jun 7, 2024
Study completion Oct 14, 2024
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Nov 30, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, care provider)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 4 years, up to 6 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main purpose of this study is to assess immune response and safety of various potencies of a measles, mumps, rubella, and varicella (MMRVNS) vaccines given to healthy children of 4 to 6 years of age.
Conditions
- Measles; Mumps; Rubella; Chickenpox
- Measles
Interventions
Investigational MMRV(H)NS vaccineBiological
1 dose of a measles, mumps, and rubella at release potency and VNS at high (H) potency vaccine administered subcutaneously.
Investigational MM(H)RVNS vaccineBiological
1 dose of a measles, rubella, and varicella at release potency and mumps at high (H) potency vaccine administered subcutaneously.
Investigational M(L)M(L)R(L)V(L)NS vaccineBiological
1 dose of measles, mumps, rubella, and varicella, all at low (L) potency vaccine administered subcutaneously.
Marketed MMRV_Lot 1 and Lot 2 vaccineBiological
1 dose of a marketed measles, mumps, rubella, and varicella of Lot 1 or 1 dose of a marketed measles, mumps, rubella, and varicella of Lot 2 vaccine administered subcutaneously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- GMC of Anti-measles Antibodies at Day 43Time frame: At Day 43
- GMC of Anti-mumps Antibodies at Day 43Time frame: At Day 43
- GMC of Anti-rubella Antibodies at Day 43Time frame: At Day 43
- GMC of Anti-glycoprotein E (gE) Antibodies at Day 43Time frame: At Day 43
Locations
47 sites in 5 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Jonesboro, Arkansas
GSK Investigational Site
Bellflower, California
GSK Investigational Site
Huntington Park, California
GSK Investigational Site
Oakland, California
GSK Investigational Site
Roseville, California
GSK Investigational Site
Sacramento, California
GSK Investigational Site
Sacramento, California
GSK Investigational Site
San Jose, California
GSK Investigational Site
Santa Clara, California
GSK Investigational Site
West Covina, California
GSK Investigational Site
Miami Lakes, Florida
GSK Investigational Site
Tampa, Florida
GSK Investigational Site
Ammon, Idaho
GSK Investigational Site
Idaho Falls, Idaho
GSK Investigational Site
Louisville, Kentucky
GSK Investigational Site
Lafayette, Louisiana
GSK Investigational Site
Boston, Massachusetts
GSK Investigational Site
Bingham Farms, Michigan
GSK Investigational Site
Detroit, Michigan
GSK Investigational Site
Lincoln, Nebraska
GSK Investigational Site
Lincoln, Nebraska
GSK Investigational Site
Omaha, Nebraska
GSK Investigational Site
Syracuse, New York
GSK Investigational Site
Cleveland, Ohio
GSK Investigational Site
Dayton, Ohio
GSK Investigational Site
Simpsonville, South Carolina
GSK Investigational Site
Tullahoma, Tennessee
GSK Investigational Site
Dickinson, Texas
GSK Investigational Site
McAllen, Texas
GSK Investigational Site
Richmond, Texas
GSK Investigational Site
Layton, Utah
GSK Investigational Site
Provo, Utah
GSK Investigational Site
Roy, Utah
GSK Investigational Site
South Jordan, Utah
GSK Investigational Site
Barranquilla, Colombia
GSK Investigational Site
Barranquilla, Colombia
GSK Investigational Site
Bogotá, Colombia
GSK Investigational Site
Riga, Latvia
GSK Investigational Site
San Juan, Puerto Rico
Showing 40 of 47 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.